Cargando…

Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters

Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-am...

Descripción completa

Detalles Bibliográficos
Autores principales: Popovici, Jean, Tebben, Kieran, Witkowski, Benoit, Serre, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851417/
https://www.ncbi.nlm.nih.gov/pubmed/33529838
http://dx.doi.org/10.1016/j.ijpddr.2020.12.004
_version_ 1783645623894933504
author Popovici, Jean
Tebben, Kieran
Witkowski, Benoit
Serre, David
author_facet Popovici, Jean
Tebben, Kieran
Witkowski, Benoit
Serre, David
author_sort Popovici, Jean
collection PubMed
description Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-aminoquinolines and among them, primaquine has been at the forefront of P. vivax case management for decades. We discuss here the possible factors that could lead to the emergence and selection of P. vivax primaquine resistant parasites and emphasize on how a better understanding of the mechanisms underlying primaquine treatment and hypnozoite biology is needed to prevent this catastrophic scenario from happening.
format Online
Article
Text
id pubmed-7851417
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78514172021-02-05 Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters Popovici, Jean Tebben, Kieran Witkowski, Benoit Serre, David Int J Parasitol Drugs Drug Resist Special issue articles on 'Drug Resistance' Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-aminoquinolines and among them, primaquine has been at the forefront of P. vivax case management for decades. We discuss here the possible factors that could lead to the emergence and selection of P. vivax primaquine resistant parasites and emphasize on how a better understanding of the mechanisms underlying primaquine treatment and hypnozoite biology is needed to prevent this catastrophic scenario from happening. Elsevier 2021-01-24 /pmc/articles/PMC7851417/ /pubmed/33529838 http://dx.doi.org/10.1016/j.ijpddr.2020.12.004 Text en © 2021 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Special issue articles on 'Drug Resistance'
Popovici, Jean
Tebben, Kieran
Witkowski, Benoit
Serre, David
Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
title Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
title_full Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
title_fullStr Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
title_full_unstemmed Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
title_short Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
title_sort primaquine for plasmodium vivax radical cure: what we do not know and why it matters
topic Special issue articles on 'Drug Resistance'
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851417/
https://www.ncbi.nlm.nih.gov/pubmed/33529838
http://dx.doi.org/10.1016/j.ijpddr.2020.12.004
work_keys_str_mv AT popovicijean primaquineforplasmodiumvivaxradicalcurewhatwedonotknowandwhyitmatters
AT tebbenkieran primaquineforplasmodiumvivaxradicalcurewhatwedonotknowandwhyitmatters
AT witkowskibenoit primaquineforplasmodiumvivaxradicalcurewhatwedonotknowandwhyitmatters
AT serredavid primaquineforplasmodiumvivaxradicalcurewhatwedonotknowandwhyitmatters